Company: Viscera Technologies
Founders: Ryan Quigley & Henry Hollamby
Website: https://www.visceraltd.com/
About Viscera Technologies
Viscera Technologies was founded by Henry Hollamby and Ryan Quigley with the aim of preventing chronic illnesses through predictive, early diagnosis by breaking down barriers to testing. The med-tech company’s flagship product, Quantico, is a platform technology designed as a universal solution for the diagnosis and monitoring of a vast array of biomarkers, using antibody-based lateral flow tests quantified through a smartphone camera. This approach eliminates the need for specialised equipment and personnel, streamlining the diagnostic process. Their motto, ‘Diagnosis. Simplified.’, reflects their commitment to making testing simple, low-cost, accurate, and convenient—evidenced by Quantico, a true point-of-care (POC) testing platform.
In 2023, Viscera secured an announced equity fundraising of £600k at a valuation of £10m. This milestone marked the company’s pivot from a singular focus on H. pylori diagnosis—a field close to the founders’ hearts, having both lost relatives to preventable gastrointestinal complications—to a versatile diagnostic testing platform capable of detecting a wide range of conditions.
With a mission to lower the barriers to diagnosis on a global scale, Viscera is dedicated to empowering both patients and healthcare providers to act before disease progression occurs. When asked how Quantico differentiates itself from existing POC tests, Henry commented, “Many tests are branded as point-of-care, yet require specialised equipment and personnel, resulting in delayed results that fall short of true point-of-care standards. Quantico changes this by enabling remote testing or administration during the initial consultation, delivering immediate results.”
The need for efficient and early diagnostics has been reinforced in recent years. As Henry and Ryan noted, “COVID has shown the public and the medical community the critical need for efficient diagnostics.” This realisation has further strengthened their commitment to early detection and proactive healthcare, driving continued innovation in the space.
Viscera’s focus on decentralising diagnosis – through bringing testing closer to patients rather than relying solely on centralised laboratories – increases accessibility, reduces turnaround times, and ultimately leads to faster, life-saving interventions. By continuously investing in research and development, the company aims to expand Quantico’s applications, transform the diagnostic landscape, and pave the way for a future where early, predictive diagnosis is accessible to all. Through Quantico, Viscera Technologies is not just improving diagnostics—it is redefining the future of healthcare, where fast, accessible, and life-saving testing is the standard, not the exception.
Check out what TechRound can do for your business: SEO, PR, HR Software, Payroll Software, IT, VoIP.
